| Management target | Revenue FY27 |
|---|
| Revenue growth | 8.6% YoY in FY26; 64% HoH growth in H2FY26. |
|---|---|
| Margins | EBITDA margin at 16.39%; PAT margin at 9.86%. |
| Demand visibility | Strong recovery in H2FY26; demand fully restored with 6300+ practitioners. |
| Management confidence | High; management highlights 'delivered as promised' after H1FY26 turnaround. |
Growth
FY26 Revenue reached INR 67 Cr with EBITDA margin improving 42 bps to 16.39%. H2FY26 saw significant 64% HoH sales recovery.
Outlook
Targeting expansion from 18 to 75 clinics by FY27 and 300 clinics long-term. Focusing on high-margin owned brands.
Risks
Historically impacted by demonetization, IL&FS default, COVID-19, and Ukraine war; currently tightening credit terms to manage receivables.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹66.00
- Market cap
- ₹93.54 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 14.1×Sector 53.1×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Business Update
Aakaar Medical Technologies provided an operational update for Q1 FY2026-27, detailing expansion in its clinic network, distributor count, and overall sales force effectiveness.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies addressed an NSE notice regarding Regulation 44(3) non-compliance, stating the lapse was inadvertent and that corrective measures have been implemented.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies submitted a share‑capital audit reconciliation reporting issued capital of ₹14.17 Crore. The filing satisfies SEBI (Depositories and Participants) Regulation 76 requirements.
- Value
- ₹14.17 Cr
Aakaar Medical Technologies Management Change
Aakaar Medical Technologies appointed NAM & ASSOCIATES as Secretarial Auditor for a five-year term. The firm brings extensive experience in corporate and foreign exchange laws.
- Execution
- 60 months
Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies held its 13th AGM on June 30, 2026. Key outcomes include financial approval and increasing authorized share capital.
Aakaar Medical Technologies Annual Report
Aakaar Medical Technologies released its FY 2025-26 annual report and scheduled its 13th AGM for June 30, 2026. The report highlights ten consecutive years of PAT positivity.